These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 28801025)

  • 21. Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.
    Druskin SC; Tosoian JJ; Young A; Collica S; Srivastava A; Ghabili K; Macura KJ; Carter HB; Partin AW; Sokoll LJ; Ross AE; Pavlovich CP
    BJU Int; 2018 Apr; 121(4):619-626. PubMed ID: 29232037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
    Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
    BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The roles of prostate-specific antigen (PSA) density, prostate volume, and their zone-adjusted derivatives in predicting prostate cancer in patients with PSA less than 20.0 ng/mL.
    Shen P; Zhao J; Sun G; Chen N; Zhang X; Gui H; Yang Y; Liu J; Shu K; Wang Z; Zeng H
    Andrology; 2017 May; 5(3):548-555. PubMed ID: 28409907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men.
    Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Jakobsen H; Thomsen HS
    Eur Urol Oncol; 2019 May; 2(3):311-319. PubMed ID: 31200846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi-institutional nomogram predicting benign prostate pathology on magnetic resonance/ultrasound fusion biopsy in men with a prior negative 12-core systematic biopsy.
    Truong M; Wang B; Gordetsky JB; Nix JW; Frye TP; Messing EM; Thomas JV; Feng C; Rais-Bahrami S
    Cancer; 2018 Jan; 124(2):278-285. PubMed ID: 28976544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men: The Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study.
    Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Winther MD; Jakobsen H; Thomsen HS
    JAMA Netw Open; 2018 Jun; 1(2):e180219. PubMed ID: 30646066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prebiopsy mp-MRI Can Help to Improve the Predictive Performance in Prostate Cancer: A Prospective Study in 1,478 Consecutive Patients.
    Wang R; Wang J; Gao G; Hu J; Jiang Y; Zhao Z; Zhang X; Zhang YD; Wang X
    Clin Cancer Res; 2017 Jul; 23(14):3692-3699. PubMed ID: 28143868
    [No Abstract]   [Full Text] [Related]  

  • 29. A Novel Nomogram to Identify Candidates for Focal Therapy Among Patients with Localized Prostate Cancer Diagnosed via Magnetic Resonance Imaging-Targeted and Systematic Biopsies: A European Multicenter Study.
    Mjaess G; Peltier A; Roche JB; Lievore E; Lacetera V; Chiacchio G; Beatrici V; Mastroianni R; Simone G; Windisch O; Benamran D; Fourcade A; Nguyen TA; Fournier G; Fiard G; Ploussard G; Roumeguère T; Albisinni S; Diamand R
    Eur Urol Focus; 2023 Nov; 9(6):992-999. PubMed ID: 37147167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic value of MRI-based PSA density in predicting transperineal sector-guided prostate biopsy outcomes.
    MacAskill F; Lee SM; Eldred-Evans D; Wulaningsih W; Popert R; Wolfe K; Van Hemelrijck M; Rottenberg G; Liyanage SH; Acher P
    Int Urol Nephrol; 2017 Aug; 49(8):1335-1342. PubMed ID: 28477301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
    Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
    J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biparametric Magnetic Resonance Imaging-Derived Nomogram to Detect Clinically Significant Prostate Cancer by Targeted Biopsy for Index Lesion.
    Kim MJ; Park SY
    J Magn Reson Imaging; 2022 Apr; 55(4):1226-1233. PubMed ID: 34296803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are prostate biopsies necessary for all patients 75years and older?
    Chen Y; Fan Y; Yang Y; Jin J; Zhou L; He Z; Zhao Z; He Q; Wang X; Yu W; Wu S
    J Geriatr Oncol; 2018 Mar; 9(2):124-129. PubMed ID: 28939384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging-detected Prostate Imaging Reporting and Data System/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score.
    Peters M; Eldred-Evans D; Kurver P; Falagario UG; Connor MJ; Shah TT; Verhoeff JJC; Taimen P; Aronen HJ; Knaapila J; Montoya Perez I; Ettala O; Stabile A; Gandaglia G; Fossati N; Martini A; Cucchiara V; Briganti A; Lantz A; Picker W; Haug ES; Nordström T; Tanaka MB; Reddy D; Bass E; van Rossum PSN; Wong K; Tam H; Winkler M; Gordon S; Qazi H; Boström PJ; Jambor I; Ahmed HU
    Eur Urol; 2022 Nov; 82(5):559-568. PubMed ID: 35963650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How to implement magnetic resonance imaging before prostate biopsy in clinical practice: nomograms for saving biopsies.
    Borque-Fernando Á; Esteban LM; Celma A; Roche S; Planas J; Regis L; de Torres I; Semidey ME; Trilla E; Morote J
    World J Urol; 2020 Jun; 38(6):1481-1491. PubMed ID: 31506748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and validation of a novel nomogram to avoid unnecessary biopsy in patients with PI-RADS category ≥ 4 lesions and PSA ≤ 20 ng/ml.
    Zeng H; Chen Y; Zhao J; Dai J; Xie Y; Wang M; Wang Q; Xu N; Chen J; Sun G; Zeng H; Shen P
    World J Urol; 2024 Aug; 42(1):495. PubMed ID: 39177844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prebiopsy multiparametric MRI-based risk score for predicting prostate cancer in biopsy-naive men with prostate-specific antigen between 4-10 ng/mL.
    Dwivedi DK; Kumar R; Dwivedi AK; Bora GS; Thulkar S; Sharma S; Gupta SD; Jagannathan NR
    J Magn Reson Imaging; 2018 May; 47(5):1227-1236. PubMed ID: 28872226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing the diagnostic performance of systematic freehand PrecisionPoint transperineal prostate biopsy: Comparison of observed outcomes to PBCG nomogram predictions.
    Setia S; Jackson J; Cendo D; Gorin MA; Allaway M; Vourganti S
    Urol Oncol; 2022 Jan; 40(1):4.e9-4.e17. PubMed ID: 34688533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A nomogram for prediction of prostate cancer on multi-core biopsy using age, serum prostate-specific antigen, prostate volume and digital rectal examination in Singapore.
    Lee A; Lim J; Gao X; Liu L; Chia SJ
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e348-e355. PubMed ID: 27641069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High cancer detection rate using cognitive fusion - targeted transperineal prostate biopsies.
    Dekalo S; Matzkin H; Mabjeesh NJ
    Int Braz J Urol; 2017; 43(4):600-606. PubMed ID: 28783264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.